Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- Reward Innovation to Solve Social Challenges: LDP Study Group
June 6, 2018
- Japan Eyes Economic Assessments for New Drug Listing: Draft Honebuto Paper
June 6, 2018
- Large Vessel Vasculitis to Be Added to Significant Adverse Reactions for G-CSF Preparations: MHLW
June 6, 2018
- Invoice Price Rates Decline Only for Long-listed Drugs at 3 Companies: MHLW Survey
June 4, 2018
- “Preclinical Registry” Will Accelerate Drug Discovery in Field of Dementia: AMED President
June 4, 2018
- AMED to Increase Transparency in Funding by Opening Up Research Database to Public
June 1, 2018
- Ex-Minister Shiozaki Holds Talks with PhRMA, EFPIA
June 1, 2018
- MHLW to End Manufacturing Record Inspection for Kaketsuken’s Plasma Fraction Products
June 1, 2018
- MHLW Positive on Enshrining Conditional Approval, Sakigake Schemes into Law: Official
May 31, 2018
- Japan’s First Biosimilars for Enbrel, Herceptin Added to NHI Price List
May 30, 2018
- Honebuto Policy Won’t Include Numerical Target for Social Security Costs
May 29, 2018
- Takeda’s Entyvio Up for MHLW Panel Review on June 8
May 28, 2018
- MHLW Grants Orphan Status to Vyndaqel, Burosumab
May 28, 2018
- MHLW OKs Add’l Indications for Xeljanz, Botox, Nucala
May 28, 2018
- MOF Pitching 2-Step Drug Price Tweaks in 2019 Tax Hike Year
May 25, 2018
- MHLW Flu Panel Approves Plan to Switch to H7N9 Strain for Pre-Pandemic Flu Vaccine
May 25, 2018
- Chuikyo Approves Insurance Reimbursement for 3 Medical Devices, with Listing Scheduled for June
May 25, 2018
- Chuikyo Tightens Physician Fee Rules for Self-Injections, Biosimilars Up for Individual Review
May 25, 2018
- Lynparza’s Breast Cancer Use, Chugai’s Obinutuzumab Clear MHLW Panel
May 24, 2018
- PMDA, FDA Team Up to Help Developing Countries to Facilitate Pediatric Drug Development
May 24, 2018
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…